Therapeutic vaccine against non-Hodgkin's lymphoma targeting the immune adjuvant properties of Natural Killer T cells.

淋巴瘤癌症患者最初对治疗反应良好，但后来因病复发。免疫系统可以有效地控制癌症。一种潜在的治疗选择是增强对癌症的自然免疫反应。这项研究调查了一种疫苗，它可以激活特定的免疫细胞NKT细胞，通过传递NKT细胞激活分子来对抗淋巴瘤。结果将允许评估以NKT为基础的疫苗与淋巴瘤现有治疗方法的结合。

Patients with lymphoma cancers initially respond well to treatment, but later relapse with disease. The immune system can be effective at controlling cancer. A potential treatment option is to boost the natural immune response against cancer. This study investigates a vaccine that activates a certain immune cell, NKT cells, to fight lymphomas by delivering an NKT cell-activating molecule. Outcomes will allow assessment of combining an NKT-based vaccine with established treatments for lymphoma.